Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05452317 · ClinicalTrials.gov registry record
Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection
A clinical trial, sponsored by CSL Behring.
- Completed
- Registry status
- 52
- Enrollment target
NCT05452317: Completed study, sponsored by CSL Behring.
NCT05452317 is a clinical trial that has completed, run by CSL Behring. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05452317 has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR
Primary Outcome
* eGFR\<15ml/min/1.73m2 for \> 60 days * Hemodialysis for \> 60 days * Nephrectomy * Re-transplant
Interventions
- OTHER Chronic active AMR group
- OTHER Non-Chronic active AMR group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2023-04-04 |
What the finished NCT05452317 record still lists
NCT05452317 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Chronic active AMR group is the first listed.
NCT05452317 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05452317 about?
NCT05452317 is a clinical study titled "Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection". This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR
What is the current status of trial NCT05452317?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2022-07-14. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT05452317?
The interventions under investigation include: Chronic active AMR group (OTHER), Non-Chronic active AMR group (OTHER).
Who is sponsoring clinical trial NCT05452317?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI